Palabras claves: Clinical trial, Ganglioside, Metastatic breast cancer, NGcGM3, Therapeutic vaccine
Autores: Arboláez M., Car A., Carmen Elena Viada, Cepeda M., De La Torre A.V., Fernandez L.E., García E., Guerra P.P., Hernandez J., Ortiz R.A., Pérez K., Toledo D.
